June 12, 2020
Denali and Sanofi pause studies with DNL747 in Alzheimer’s and ALS (edited)
Denali Therapeutics and Sanofi have paused clinical studies with small molecule RIPK1 inhibitor DNL747 in Alzheimer’s disease and ALS, due to emerging evidence that higher levels of target inhibition may be required for maximizing efficacy, and certain challenges.